Xenetic Biosciences, Inc. (NASDAQ:XBIO) Short Interest Down 44.2% in June

Xenetic Biosciences, Inc. (NASDAQ:XBIO) was the target of a significant decline in short interest in June. As of June 15th, there was short interest totaling 9,143 shares, a decline of 44.2% from the May 31st total of 16,388 shares. Currently, 0.4% of the company’s shares are short sold. Based on an average daily trading volume, of 19,697 shares, the days-to-cover ratio is presently 0.5 days.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Xenetic Biosciences in a research note on Monday, April 20th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Xenetic Biosciences presently has an average rating of “Sell”.

Xenetic Biosciences Stock Performance

NASDAQ XBIO traded down $0.11 during trading hours on Thursday, hitting $2.83. 12,166 shares of the company’s stock were exchanged, compared to its average volume of 20,543. The business’s 50 day moving average is $3.05 and its 200-day moving average is $2.71. Xenetic Biosciences has a 12-month low of $1.90 and a 12-month high of $13.93. The firm has a market capitalization of $6.48 million, a P/E ratio of -2.36 and a beta of 2.19.

Xenetic Biosciences (NASDAQ:XBIO) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.20) EPS for the quarter. The business had revenue of $0.81 million during the quarter. Xenetic Biosciences had a negative net margin of 70.03% and a negative return on equity of 39.28%.

Hedge Funds Weigh In On Xenetic Biosciences

A hedge fund recently bought a new stake in Xenetic Biosciences stock. DRW Securities LLC purchased a new stake in shares of Xenetic Biosciences, Inc. (NASDAQ:XBIO) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 13,824 shares of the company’s stock, valued at approximately $30,000. DRW Securities LLC owned 0.60% of Xenetic Biosciences as of its most recent filing with the Securities and Exchange Commission. 15.12% of the stock is owned by hedge funds and other institutional investors.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.